Literature DB >> 19682749

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication.

Sagar V Parikh1, Zindel V Segal, Sophie Grigoriadis, Arun V Ravindran, Sidney H Kennedy, Raymond W Lam, Scott B Patten.   

Abstract

BACKGROUND: In 2001, the Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments (CANMAT) partnered to produce evidence-based clinical guidelines for the treatment of depressive disorders. A revision of these guidelines was undertaken by CANMAT in 2008-2009 to reflect advances in the field. This article, one of five in the series, reviews new studies of psychotherapy in the acute and maintenance phase of MDD, including computer-based and telephone-delivered psychotherapy.
METHODS: The CANMAT guidelines are based on a question-answer format to enhance accessibility to clinicians. Evidence-based responses are based on updated systematic reviews of the literature and recommendations are graded according to the Level of Evidence, using pre-defined criteria. Lines of Treatment are identified based on criteria that included evidence and expert clinical support.
RESULTS: Cognitive-Behavioural Therapy (CBT) and Interpersonal Therapy (IPT) continue to have the most evidence for efficacy, both in acute and maintenance phases of MDD, and have been studied in combination with antidepressants. CBT is well studied in conjunction with computer-delivered methods and bibliotherapy. Behavioural Activation and Cognitive-Behavioural Analysis System of Psychotherapy have significant evidence, but need replication. Newer psychotherapies including Acceptance and Commitment Therapy, Motivational Interviewing, and Mindfulness-Based Cognitive Therapy do not yet have significant evidence as acute treatments; nor does psychodynamic therapy. LIMITATIONS: Although many forms of psychotherapy have been studied, relatively few types have been evaluated for MDD in randomized controlled trials. Evidence about the combination of different types of psychotherapy and antidepressant medication is also limited despite widespread use of these therapies concomitantly.
CONCLUSIONS: CBT and IPT are the only first-line treatment recommendations for acute MDD and remain highly recommended for maintenance. Both computer-based and telephone-delivered psychotherapy--primarily studied with CBT and IPT--are useful second-line recommendations. Where feasible, combined antidepressant and CBT or IPT are recommended as first-line treatments for acute MDD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19682749     DOI: 10.1016/j.jad.2009.06.042

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  41 in total

1.  The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo.

Authors:  Mark Hyman Rapaport; Andrew A Nierenberg; Robert Howland; Christina Dording; Pamela J Schettler; David Mischoulon
Journal:  J Psychiatr Res       Date:  2011-05-31       Impact factor: 4.791

2.  Treatment-resistant depression in later life.

Authors:  Heba El Bayoumi; Zahinoor Ismail
Journal:  J Psychiatry Neurosci       Date:  2015-11       Impact factor: 6.186

3.  Improving Access to Psychosocial Treatments--Integrating Patient, Provider, and Systems Approaches.

Authors:  Sagar V Parikh
Journal:  Can J Psychiatry       Date:  2015-06       Impact factor: 4.356

4.  Impact of deductibles on initiation and continuation of psychotherapy for treatment of depression.

Authors:  Paul A Fishman; Victoria Ding; Rebecca Hubbard; Evette J Ludman; Chester Pabiniak; Christine Stewart; Leo Morales; Gregory E Simon
Journal:  Health Serv Res       Date:  2012-02-29       Impact factor: 3.402

Review 5.  Effectiveness of psychological treatments for depressive disorders in primary care: systematic review and meta-analysis.

Authors:  Klaus Linde; Kirsten Sigterman; Levente Kriston; Gerta Rücker; Susanne Jamil; Karin Meissner; Antonius Schneider
Journal:  Ann Fam Med       Date:  2015 Jan-Feb       Impact factor: 5.166

6.  Making Evidence-Based Psychotherapy More Accessible in Canada.

Authors:  David Gratzer; David Goldbloom
Journal:  Can J Psychiatry       Date:  2016-04-05       Impact factor: 4.356

Review 7.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments.

Authors:  Sagar V Parikh; Lena C Quilty; Paula Ravitz; Michael Rosenbluth; Barbara Pavlova; Sophie Grigoriadis; Vytas Velyvis; Sidney H Kennedy; Raymond W Lam; Glenda M MacQueen; Roumen V Milev; Arun V Ravindran; Rudolf Uher
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 8.  Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2017-04-11

9.  The diagnosis of depression and its treatment in Canadian primary care practices: an epidemiological study.

Authors:  Sabrina T Wong; Donna Manca; David Barber; Rachael Morkem; Shahriar Khan; Jyoti Kotecha; Tyler Williamson; Richard Birtwhistle; Scott Patten
Journal:  CMAJ Open       Date:  2014-10-01

Review 10.  Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder.

Authors:  Ashwin A Patkar; Chi-Un Pae
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.